Drug Topics May 17, 2024
Amgen’s Tarlatamab-dlle (Imdelltra) is the first and only approved DLL3-targeting bispecific T-cell engager therapy for the aggressive form of lung cancer.
The FDA has granted accelerated approval to tarlatamab-dlle (Imdelltra) for the treatment of extensive-stage small cell lung cancer (SCLC) in adults with disease progression on or after platinum-based chemotherapy, Amgen announced in a news release.1 Tarlatamab-dlle is now the first and only approved DLL3-targeting bispecific T-cell engager therapy for the aggressive form of lung cancer.
The approval of tarlatamab-dlle was based on data from the DeLLphi-301 trial (NCT05060016), in which the therapy demonstrated antitumor activity with durable objective responses and promising survival outcomes when administered as a 10 mg dose every 2 weeks. Results from the trial were published...
Today's Sponsors
Today's Sponsor